Restoring hippocampal glucose metabolism rescues cognition across Alzheimer's disease pathologies

Paras S Minhas,Jeffrey R Jones,Amira Latif-Hernandez,Yuki S Sugiura,Aarooran Durairaj,Takeshi Uenaka,Qian Wang,Siddhita D Mhatre,Ling Liu,Travis Conley,Hannah Ennerfelt,Yoo Jin Jung,Praveena Prasad,Brenita C Jenkins,Ryan Goodman,Traci F Newmeyer,Kelly Heard,Austin Kang,Edward N Wilson,Erik M Ullian,Geidy E Serrano,Thomas G Beach,Joshua D Rabinowitz,Marius Wernig,Makoto Suematsu,Frank M Longo,Melanie R McReynolds,Fred H Gage,Katrin I Andreasson

DOI: https://doi.org/10.1101/2024.06.23.598940

2024-06-28

Abstract:Impaired cerebral glucose metabolism is a pathologic feature of Alzheimer Disease (AD), and recent proteomic studies highlight a disruption of glial carbohydrate metabolism with disease progression. Here, we report that inhibition of indoleamine-2,3-dioxygenase 1 (IDO1), which metabolizes tryptophan to kynurenine (KYN) in the first step of the kynurenine pathway, rescues hippocampal memory function and plasticity in preclinical models of amyloid and tau pathology by restoring astrocytic metabolic support of neurons. Activation of IDO1 in astrocytes by amyloid-beta42 and tau oligomers, two major pathological effectors in AD, increases KYN and suppresses glycolysis in an AhR-dependent manner. Conversely, pharmacological IDO1 inhibition restores glycolysis and lactate production. In amyloid-producing APPSwe-PS1∆E9 and 5XFAD mice and in tau-producing P301S mice, IDO1 inhibition restores spatial memory and improves hippocampal glucose metabolism by metabolomic and MALDI-MS analyses. IDO1 blockade also rescues hippocampal long-term potentiation (LTP) in a monocarboxylate transporter (MCT)-dependent manner, suggesting that IDO1 activity disrupts astrocytic metabolic support of neurons. Indeed, in vitro mass-labeling of human astrocytes demonstrates that IDO1 regulates astrocyte generation of lactate that is then taken up by human neurons. In co-cultures of astrocytes and neurons derived from AD subjects, deficient astrocyte lactate transfer to neurons was corrected by IDO1 inhibition, resulting in improved neuronal glucose metabolism. Thus, IDO1 activity disrupts astrocytic metabolic support of neurons across both amyloid and tau pathologies and in a model of AD iPSC-derived neurons. These findings also suggest that IDO1 inhibitors developed for adjunctive therapy in cancer could be repurposed for treatment of amyloid- and tau-mediated neurodegenerative diseases.

Neuroscience

What problem does this paper attempt to address?

This paper attempts to address a key metabolic defect in Alzheimer's Disease (AD). Specifically, the study found that indoleamine 2,3-dioxygenase 1 (IDO1) is overactivated in the pathological process of AD, leading to impaired glucose metabolism in the brain and affecting the supportive function of neurons. Researchers restored memory function and synaptic plasticity in the hippocampus by inhibiting IDO1, thereby improving cognitive impairment in AD models.

### Main Research Content:
1. **Relationship between IDO1 and KYN**: The study found that amyloid-β and tau oligomers activate IDO1 in astrocytes, generating kynurenine (KYN), which in turn inhibits glycolysis and lactate production.
2. **Effects of IDO1 Inhibition**: By gene knockout or pharmacological inhibition of IDO1, glycolysis, lactate production, and glucose metabolism in the hippocampus can be restored.
3. **Validation in Multiple AD Models**: In different AD models (including amyloid-β accumulation models and tau protein accumulation models), IDO1 inhibition was able to restore spatial memory and long-term potentiation (LTP).
4. **Validation in Human Cells**: In astrocytes derived from induced pluripotent stem cells (iPSCs) from AD patients, IDO1 inhibition similarly restored lactate production and neuronal energy metabolism.

### Conclusion:
This study indicates that IDO1 activity and its generated KYN inhibit the supportive function of astrocytes to neurons in the pathological process of AD. By inhibiting IDO1, glucose metabolism and cognitive function in the hippocampus can be restored, providing a new potential strategy for the treatment of AD.